Literature DB >> 33795324

Continuous positive airway pressure improves blood pressure and serum cardiovascular biomarkers in obstructive sleep apnoea and hypertension.

Macy Mei-Sze Lui1, Hung-Fat Tse2, David Chi-Leung Lam1, Kui-Kai Lau3, Carmen Wing-Sze Chan2, Mary Sau-Man Ip4.   

Abstract

BACKGROUND: The impact of treatment for obstructive sleep apnoea (OSA) on reduction of cardiovascular risk is unclear. This study aimed to examine the effect of continuous positive airway pressure (CPAP) on ambulatory blood pressure (BP) and subclinical myocardial injury in subjects with OSA and hypertension.
METHODS: This was a parallel-group randomised controlled trial. Subjects with hypertension requiring at least three antihypertensive medications and moderate-to-severe OSA were enrolled. Eligible subjects were randomised (1:1) to receive either CPAP treatment or control (no CPAP) for 8 weeks. Changes in ambulatory BP and serum biomarkers were compared. Stratified analysis according to circadian BP pattern was performed.
RESULTS: 92 subjects (75% male; mean±sd age 51±8 years and apnoea-hypopnoea index 40±8 events·h-1, taking an average of 3.4 (range 3-6) antihypertensive drugs) were randomised. The group on CPAP treatment, compared with the control group, demonstrated a significant reduction in 24-h systolic BP (-4.4 (95% CI -8.7- -0.1) mmHg; p=0.046), 24-h diastolic BP (-2.9 (95% CI -5.5- -0.2) mmHg; p=0.032), daytime systolic BP (-5.4 (95% CI -9.7- -1.0) mmHg; p=0.016) and daytime diastolic BP (-3.4 (95% CI -6.1- -0.8) mmHg; p=0.012). CPAP treatment was associated with significant BP lowering only in nondippers, but not in dippers. Serum troponin I (mean difference -1.74 (95% CI -2.97- -0.50) pg·mL-1; p=0.006) and brain natriuretic peptide (-9.1 (95% CI -17.6- -0.6) pg·mL-1; p=0.036) were significantly reduced in CPAP compared with the control group.
CONCLUSIONS: In a cohort with OSA and multiple cardiovascular risk factors including difficult-to-control hypertension, short-term CPAP treatment improved ambulatory BP, and alleviated subclinical myocardial injury and strain.
Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33795324     DOI: 10.1183/13993003.03687-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

Review 1.  Research trends in hypertension associated with obstructive sleep apnea: a bibliometric analysis.

Authors:  Yirou Niu; Hongwei Cai; Wei Zhou; Haiyan Xu; Xiaodan Dong; Shuang Zhang; Jiaxin Lan; Lirong Guo
Journal:  Sleep Breath       Date:  2022-05-17       Impact factor: 2.816

2.  Benefits of continuous positive airway pressure on blood pressure in patients with hypertension and obstructive sleep apnea: a meta-analysis.

Authors:  Wenli Shang; Yingying Zhang; Lu Liu; Fenfen Chen; Guizuo Wang; Dong Han
Journal:  Hypertens Res       Date:  2022-06-14       Impact factor: 3.872

Review 3.  Current and novel treatment options for obstructive sleep apnoea.

Authors:  Winfried Randerath; Jan de Lange; Jan Hedner; Jean Pierre T F Ho; Marie Marklund; Sofia Schiza; Jörg Steier; Johan Verbraecken
Journal:  ERJ Open Res       Date:  2022-06-27

4.  Effect of positive airway pressure on cardiac troponins in patients with sleep-disordered breathing: A meta-analysis.

Authors:  Li-Hua Wu; Cai-Xia Hong; Zhi-Wei Zhao; Yan-Fei Huang; Huo-Yu Li; Hong-Ling Cai; Zhi-Sen Gao; Zhi Wu
Journal:  Clin Cardiol       Date:  2022-03-21       Impact factor: 3.287

5.  High-sensitive cardiac troponin after CPAP in obstructive sleep apnoea: the adjusted analytical change limit (adjACL) for small variations at low concentrations.

Authors:  Denis Monneret
Journal:  Eur Respir J       Date:  2022-02-17       Impact factor: 16.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.